No Data
No Data
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $92
Morgan Stanley analyst Jeffrey Hung maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating, and maintains the target price at $92.According to TipRanks data, the analyst has a success rate
Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)
BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return
RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $107
RBC Capital analyst Brian Abrahams maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating, and adjusts the target price from $103 to $107.According to TipRanks data, the analyst has a
Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital
Express News | Intra-Cellular Therapies Inc : RBC Raises Target Price to $107 From $103